Please ensure Javascript is enabled for purposes of website accessibility

Report: Gilead Is Considering Taking a Stake in Arcus Biosciences

By Eric Volkman - Apr 16, 2020 at 2:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The two companies are apparently discussing either an equity purchase or some other form of cooperation.

Gilead Sciences (GILD 0.82%), a busy company these days, might be adding another significant investment to its agenda. An article published by Bloomberg after the market closed Wednesday, citing "people familiar with the matter," asserted that the biotech giant is mulling the purchase of a stake in Arcus Biosciences (RCUS 5.10%).

The two companies have had talks on the matter, but have also discussed merely entering into some development partnerships, according to the article's sources.

Arcus is a biotech that concentrates on oncology, an area of significant interest for Gilead. It has significantly boosted its presence in the segment, most recently by striking a deal to buy immuno-oncology specialist Forty Seven for $4.9 billion.

Pills spilling out onto U.S. currency.

Image source: Getty Images.

At the moment, Google parent Alphabet has the largest stake in Arcus, with an approximate 11% holding. It first invested in the company in 2017 in an early funding round; the following year, Arcus held its initial public offering. The Bloomberg article did not mention whether Alphabet participated in the reported discussions between Gilead and Arcus. None of those companies has yet commented on the article.

Although Gilead has a particular interest in oncology, its profile has risen lately because it owns one of the drugs that has gotten considerable attention as a potential treatment for COVID-19, the disease caused by the SARS-CoV-2 coronavirus. The antiviral drug remdesivir, originally developed to treat Ebola, is now in clinical trials  for COVID-19, and is also being administered to some patients outside the studies under the compassionate-use protocol.

On Wednesday, shares of both Gilead and Arcus declined more sharply than the key equities indexes -- the former by 4%, and the latter by 7.2%. But by late afternoon Thursday, Arcus was trading more than 80% higher, while Gilead had gained about 2%.

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), and Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.96 (0.82%) $0.51
Arcus Biosciences, Inc. Stock Quote
Arcus Biosciences, Inc.
$27.20 (5.10%) $1.32
Alphabet Inc. Stock Quote
Alphabet Inc.
$121.68 (2.39%) $2.84
Alphabet Inc. Stock Quote
Alphabet Inc.
$122.65 (2.36%) $2.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.